Trial intelligence / Profile preview

Amivantamab + capmatinib in unresectable metastatic non-small cell lung cancer

CTR20230849Phase 2Active

Sponsor

Janssen Pharmaceutical

Start

Dec 2023

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1